Miriam Monge to Join Sartorius Stedim Biotech as Director of Marketing for Integrated Solutions
Sartorius Stedim Biotech (SSB), has appointed Miriam Monge as Director of Marketing for SSB’s Integrated Solutions unit. In this newly created position, Monge will focus on sharpening SSB’s profile as an integrated solution provider for the biopharmaceutical industry.
Miriam Monge brings in more than 20 years of experience in the biopharmaceutical manufacturing sector and served, most recently, as Vice President of Sales & Marketing at the consultancy Biopharm Services. She is a committee member of the International Society for Pharmaceutical Engineering (ISPE) and one of the founders of the Global Disposable Community of Practice. Miriam Monge regularly authors articles for technical bioprocess journals, analysing the impact of disposable technologies on biomanufacturing.
“With Miriam Monge, we have gained an internationally recognised expert from the biopharmaceutical industry who will help us further position Sartorius Stedim Biotech as a total solution provider for biopharma companies, “ stated Reinhard Vogt, member of the SSB Board of Directors. “Whenever our customers start planning a new facility or process, SSB’s Integrated Solutions unit is an ideal partner for designing and implementing entire single-use or hybrid production processes.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.